

1 **YAP promotes cell-autonomous immune responses to tackle**  
2 **intracellular *Staphylococcus aureus* in vitro**

3

4 Caire Robin<sup>1\*</sup>, Audoux Estelle<sup>1</sup>, Thomas Mireille<sup>2</sup>, Dalix Elisa<sup>2</sup>, Peyron Aurélien<sup>1</sup>, Rodriguez  
5 Killian<sup>1</sup>, Dickerscheit Yann<sup>1</sup>, Marotte Hubert<sup>2</sup>, Vandenesch François<sup>3,4</sup>, Laurent Frédéric<sup>3,4</sup>,  
6 Josse Jérôme<sup>4</sup>, Verhoeven Paul. O<sup>1,5\*</sup>

7

8 <sup>1</sup> CIRI, Centre International de Recherche en Infectiologie, GIMAP Team, Univ Lyon, Univ St-  
9 Etienne, INSERM U1111, CNRS UMR5308, ENS de Lyon, Université Claude Bernard Lyon  
10 1, St-Etienne, France.

11 <sup>2</sup> SAINBIOSE, U1059-INSERM, Université de Lyon, St-Etienne, France

12 <sup>3</sup> CIRI, Centre International de Recherche en Infectiologie, Team Staphylococcal  
13 Pathogenesis, Univ Lyon, INSERM U1111, CNRS UMR5308, ENS de Lyon, Université  
14 Claude Bernard Lyon 1, Lyon, France.

15 <sup>4</sup> Department of Bacteriology, Institute for infectious Agents, Hospices Civiles de Lyon, Lyon,  
16 France.

17 <sup>5</sup> Department of Infectious Agents and Hygiene, University Hospital of St-Etienne, St-Etienne,  
18 France.

19


20 \*Correspondence:

21 -paul.verhoeven@univ-st-etienne.fr

22 Address: Service de Agents Infectieux et d'Hygiène, CHU de St-Etienne, 42270 St Priest-en-  
23 Jarez, France. Phone/Fax number: +33 477829228 / +33 477828460

24 -caire.robin@gmail.com

25 GRAPHICAL ABSTRACT



26 **ABSTRACT**

27

28 Transcriptional cofactors YAP/TAZ have recently been found to support autophagy and  
29 inflammation, which are part of cell autonomous immunity and are critical in antibacterial  
30 defense. Here, we studied the role of YAP against *Staphylococcus aureus* using  
31 CRISPR/Cas9-mutated HEK293 cells and a primary cell-based organoid model. We found  
32 that *S. aureus* infection increases YAP transcriptional activity, which is required to reduce  
33 intracellular *S. aureus* replication. A 770-gene targeted transcriptomic analysis revealed that  
34 YAP upregulates genes involved in autophagy/lysosome and inflammation pathways in both  
35 infected and uninfected conditions. The YAP/TEAD transcriptional activity promotes  
36 autophagic flux and lysosomal acidification, which are important for defense against  
37 intracellular *S. aureus*. Furthermore, the staphylococcal toxin C3 exoenzyme EDIN-B was  
38 found effective in preventing YAP-mediated cell-autonomous immune response. This study  
39 provides new insights on the anti-*S. aureus* activity of YAP, which could be conserved for  
40 defense against other intracellular bacteria.

41

42 **KEYWORDS**

43

44 YAP, *Staphylococcus aureus*, autophagy, lysosome, inflammation, C3 exoenzyme, EDIN,  
45 cell-autonomous immunity, host response genes.

## 46 INTRODUCTION

47

48 Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ)  
49 are transcriptional co-factors involved in many basic cellular functions. YAP and TAZ could  
50 interact with TEA domain transcription factor (TEAD), their main transcriptional partner, to  
51 elicit target gene expression <sup>1,2</sup>. This interaction occurs through the TEAD-binding domain  
52 (TBD) of YAP, which is highly conserved throughout evolution <sup>3,4</sup>. The Hippo pathway was  
53 the first described mechanism for YAP/TAZ phosphorylation that leads to its cytoplasmic  
54 retention or proteasomal degradation <sup>5,6</sup>. Additionally, YAP/TAZ act as major  
55 mechanotransducers that integrate mechanical *stimuli* into transcriptional responses <sup>7</sup>. The  
56 subcellular localization and nuclear translocation of YAP are regulated by the Rho family of  
57 GTPases and actin tension<sup>7-9</sup>. At low cell density, YAP exists in the nucleus and is  
58 transcriptionally active, whereas at high cell density, it remains in the cytoplasm <sup>8</sup>. The  
59 YAP/TAZ transcriptional program has been extensively studied in cancer research because it  
60 promotes cancer cell survival, proliferation, and invasiveness <sup>10</sup>. Growing evidence suggests  
61 that YAP/TAZ are inflammation-responsive and promote inflammation, as well as immune  
62 pro-inflammatory cell differentiation <sup>11-13</sup>. Recent studies have highlighted the role of  
63 YAP/TAZ in autophagy through the transcription of genes encoding proteins involved in the  
64 formation autophagosomes or their fusion with lysosomes <sup>14,15</sup>. Autophagy against  
65 intracellular pathogens (formerly called xenophagy) is used by virtually any cell type.  
66 Autophagy and inflammation are conserved cell-autonomous responses that restrict infection  
67 and increase specialized immune cell recruitment for pathogen clearance <sup>16,17</sup>. Despite its  
68 involvement in autophagy and inflammation, the modulation and role of YAP during bacterial  
69 infections remain poorly investigated, and the findings are somewhat controversial.  
70 *Helicobacter pylori* infection in gastric cells (in vitro) leads to YAP transcriptional activation  
71 and inflammation (increased IL-1B expression), which, in turn, promotes tumorigenesis <sup>18</sup>.  
72 YAP transcriptional activity in B cells has been found to promote inflammasome activation  
73 and likely contribute to defense against *Salmonella* infection in vitro <sup>19</sup>. In a mouse model of

74 pneumonia due to *Streptococcus pneumoniae*, alveolar cells exhibited increased YAP/TAZ  
75 activity, which is important for tissue healing as well as reducing NF- $\kappa$ B activity<sup>20</sup>. In *C.*  
76 *elegans* and mice, YAP is required to control intestinal infection by *Pseudomonas aeruginosa*  
77 and *Salmonella typhimurium*<sup>21</sup>. In contrast, Yorkie (YAP homolog in *Drosophila*  
78 *melanogaster*) transcriptional activity was found to inhibit the production of anti-microbial  
79 peptides by inhibiting NF- $\kappa$ B activity and fostering infection with gram-positive bacteria<sup>22</sup>. In  
80 addition, indirect observations could link YAP and bacterial infections. Indeed, C3  
81 exoenzyme ADP-ribosyltransferase, a bacterial toxin secreted by *Clostridium botulinum*, is  
82 known to be a highly specific RhoA inhibitor<sup>23</sup>. This commercially available toxin is  
83 commonly used to inhibit YAP activity *in vitro*<sup>7</sup>. It is also noteworthy that many intracellular  
84 bacterial species can produce C3-like and other toxins that are potent RhoA inhibitors<sup>24,25</sup>.  
85 For instance, epidermal cell differentiation inhibitors (EDINs) produced by *Staphylococcus*  
86 *aureus* belong to the *Clostridium botulinum* C3 exoenzyme family of bacterial ADP-  
87 ribosyltransferases<sup>26</sup>. The EDIN-B-expressing *S. aureus* clone ST80-MRSA-IV was found to  
88 inhibit RhoA activity *in vitro*<sup>27</sup>. In humans, the prevalence of *edin*-positive *S. aureus* strains is  
89 associated with deep-seated infections of soft tissues, suggesting that EDINs increase the  
90 virulence of *S. aureus in vivo*<sup>28</sup>. Despite the strong ability of the C3 exoenzyme to inhibit  
91 YAP transcriptional activity, whether the intracellular production of C3 exoenzymes, such as  
92 EDINs, could foster *S. aureus* infection through YAP inhibition remains unknown.

93 *Staphylococcus aureus* is both a commensal and a life-threatening human pathogen  
94 responsible for various infections, such as soft skin tissue infections, bacteremia,  
95 endocarditis, and osteoarticular infections<sup>29</sup>. It is widely recognized as a facultative  
96 intracellular bacterium capable of triggering its internalization inside non-professional  
97 phagocytic cells (NPPCs) by interacting with different host cell receptors<sup>30</sup>. Inside the host  
98 cell, *S. aureus* has been found to be engulfed in autophagosomes by selective autophagy  
99 involving cargo receptor proteins, such as sequestosome 1 (SQSTM1/P62), restricting  
100 intracellular *S. aureus*<sup>31</sup>. Autophagy has been shown to be a critical mechanism in defense  
101 against *S. aureus* infection in mice and zebrafish<sup>32,33</sup>.

102           In this study, we investigated the potential antibacterial role of the YAP/TEAD  
103 transcriptional program using *S. aureus* infection in HEK293 cells and synovial organoid-  
104 based models. We showed that YAP/TEAD transcriptional activity is involved in xenophagy  
105 because it enhances autophagic flux to promote *S. aureus* clearance. Further, we showed  
106 that YAP mediates the expression of host response genes that are known to be important for  
107 clearing bacterial infections. In addition, we demonstrated that EDIN-B-producing *S. aureus*  
108 prevents YAP/TEAD transcriptional activity and fosters intracellular bacterial replication.

109 **RESULTS**

110

111 ***Staphylococcus aureus* infection elicits YAP transcriptional activity prevented by the**  
112 **expression of the *edinB* gene**

113 In this study, we used a lysostaphin (a non-cell permeable bacteriocin active against *S.*  
114 *aureus*) protection assay-based model<sup>34</sup> to focus on intracellular bacteria and avoid  
115 uncontrolled extracellular bacterial replication.

116 To investigate YAP signaling in response to *S. aureus* infection, we first used the HG001 *S.*  
117 *aureus* strain (that lacks *edin* genes) in HEK293 cells at different cell densities. At high cell  
118 density (HD), YAP was mainly cytoplasmic, as expected (**Figure 1A**). In this scenario, *S.*  
119 *aureus* induced an increase in YAP nuclear mean fluorescence intensity (MFI) but not in  
120 cytoplasmic MFI, resulting in an increase in the YAP nuclear cytoplasmic (NC) ratio at 7 h  
121 post infection (hpi) (**Figure 1A-D**). In contrast, at low cell density (LD) (i.e., when cells are  
122 completely isolated from each other, and YAP is exclusively localized in the nucleus) YAP  
123 remained localized in the nucleus upon *S. aureus* infection (**S. Figure 1A**). Immunoblotting  
124 showed that *S. aureus* did not change YAP and TAZ total protein levels at medium cell  
125 density (MD) (i.e., when cells formed few contacts and YAP was mainly localized in the  
126 nucleus) (**S. Figure 1B-D**). In MD, neither the activity of TEAD nor the expression of  
127 cysteine-rich inducer 61 (*CYR61*), which is a YAP/TAZ/TEAD target gene, was modified  
128 upon *S. aureus* infection (**S. Figure 1E-G**). Thus, *S. aureus* HG001 strain infection was  
129 found to trigger YAP nuclear translocation but did not enhance YAP signaling when it was  
130 already active. We then tested whether the C3 exoenzyme EDIN-B secreted by the *S.*  
131 *aureus* ST80-MRSA-IV strain could prevent YAP activation. Given that the *edinB*-encoded  
132 C3 exoenzyme is a membrane non-permeable toxin<sup>35</sup>, cells were incubated with *S. aureus*  
133 culture supernatants for 24 h to allow the toxin to enter cells. We found that the culture  
134 supernatant of the ST80 wild-type (WT) strain reduced the nuclear and cytoplasmic  
135 localization of YAP, resulting in a decrease in the YAP NC ratio in cells at HD (**S. Figure 2A-**  
136 **D**) and an inhibition of TEAD transcriptional activity at LD (**Figure 1F**). In contrast, the culture

137 supernatant of the *edinB*-deleted ST80-MRSA-IV strain (ST80  $\Delta edinB$ ) had no effect on YAP  
138 localization and TEAD activity (**Figure 1F and S. Figure 2A-D**). Together, these results  
139 demonstrate that *S. aureus* EDIN-B toxin is highly effective in inhibiting YAP/TEAD activity.  
140 *Staphylococcus aureus* has been shown to be more efficient in delivering EDIN-B directly  
141 into the host cell after internalization<sup>35</sup>. Consequently, we tested whether infection with the  
142 ST80 WT and ST80  $\Delta edinB$  strains modulates YAP subcellular localization and  
143 transcriptional activity. As expected, the ST80  $\Delta edinB$  strain was found to enhance YAP  
144 nuclear intensity and decrease YAP cytoplasmic intensity, resulting in a strong increase in  
145 the YAP NC ratio (**Figure 1A-D**) at 7 hpi in HD cells. In contrast, the EDIN-B-expressing  
146 ST80 WT strain was found to reduce YAP nuclear MFI and NC ratio compared to ST80  
147  $\Delta edinB$  at 7 hpi in HD cells as well as YAP cytoplasmic and nuclear MFI compared to the  
148 control cells (**Figure 1A-D**). In addition, ST80  $\Delta edinB$  was found to increase TEAD  
149 transcriptional activity as soon as 3 hpi in HD cells, whereas it was not the case with the  
150 ST80 WT strain (**Figure 1E**). These results demonstrated that the *S. aureus* infection (but  
151 not the *S. aureus* supernatant) caused an increase in YAP nuclear localization and  
152 YAP/TEAD transcriptional activity *in vitro*. Interestingly, the EDIN-B-expressing ST80 WT  
153 strain as well as the EDIN-B toxin alone were found to be effective in preventing or  
154 decreasing YAP activity.

155

156 **YAP transcriptional activity is required to limit the intracellular replication of *S. aureus***  
157 As YAP is activated during infection, we investigated whether YAP/TEAD transcriptional  
158 activity was needed to fight *S. aureus in vitro*. We used WT and YAP-deleted (YAP<sup>-/-</sup>)  
159 HEK293 cells generated using the CRISPR-Cas9 technique<sup>36</sup>. YAP knockout was confirmed  
160 by immunoblotting, and the absence of YAP transcriptional activity was confirmed by a  
161 decrease in *CYR61* expression by RT-qPCR (**S. Figure 1B, C, and G**). Interestingly, YAP  
162 knockout decreased TAZ total protein levels (**S. Figure 1B and D**), which can contribute to  
163 decreased TEAD transcriptional activity. To specifically investigate the role of YAP/TEAD  
164 activity, we engineered HEK293 cells with a heterozygote mutation of YAP within its TEAD-



165 binding domain (YAP $\Delta$ TEAD<sup>+/+</sup>) that resulted in the substitution of four amino acids (**Figure**  
166 **2A**) critical for binding to TEAD<sup>4</sup>. In LD cells, YAP/TEAD activity was strongly decreased in  
167 YAP $\Delta$ TEAD<sup>+/+</sup> cells compared to WT cells (**Figure 2B**). Subsequent experiments were  
168 performed at MD to have a robust basal activity of YAP in WT cells, compared to YAP-  
169 mutated cells (i.e., YAP<sup>-/-</sup> and YAP $\Delta$ TEAD<sup>+/+</sup> cells). Using the DsRed-expressing *S. aureus*  
170 HG001 strain, we first observed by confocal microscopy that *S. aureus* was able to replicate  
171 in WT cells between 3 and 7 hpi. Strikingly, *S. aureus* intracellular replication was more  
172 pronounced in both YAP<sup>-/-</sup> and YAP $\Delta$ TEAD<sup>+/+</sup> cells, with the presence of heavily infected cells  
173 (**Figure 2C and D**). These results were confirmed by quantifying intracellular *S. aureus* loads  
174 on agar plates (**Figure 2E**). Interestingly, in WT cells, the intracellular replication of the ST80  
175 WT strain was more pronounced than that of the ST80  $\Delta$ EB strain, showing that EDIN-B  
176 expression was an advantage for *S. aureus* intracellular replication *in vitro* (**Figure 2C, F**).  
177 Thus, YAP/TEAD activity and EDIN-B expression exerted opposite effects by restricting and  
178 enhancing the intracellular replication of *S. aureus*, respectively.

179

## 180 **YAP is critical to promote the expression of host response genes usually induced by** 181 ***S. aureus* infection**

182 To understand why YAP transcriptional activity was important in inhibiting *S. aureus*  
183 intracellular replication, we analyzed the expression of 770 genes involved in host response  
184 in control or HG001-infected WT or YAP<sup>-/-</sup> cells at 7 hpi and at MD using the nCounter host  
185 response panel. Since we showed that *S. aureus* did not increase YAP activity at this cell  
186 density, we focused more on the differences between YAP<sup>-/-</sup> and WT cells in both uninfected  
187 and infected conditions.

188 Striking differences were observed between WT and YAP<sup>-/-</sup> cells under both uninfected and  
189 infected conditions. For instance, 240 genes were downregulated, whereas only 52 were  
190 upregulated in YAP<sup>-/-</sup> infected cells compared to WT infected cells. Most of the  
191 downregulated signaling pathways in YAP<sup>-/-</sup> cells were inflammation-related signaling  
192 pathways (e.g., chemokine, interleukin, inflammasome, and prostaglandin signaling

193 pathways) (**Figure 3A**). Upon *S. aureus* infection in WT cells, a pro-inflammatory response  
194 profile was induced, whereas in YAP<sup>-/-</sup> cells, this response was induced but remained at  
195 lower levels than that in WT control or infected cells (**Figure 3A**). At the level of individual  
196 genes, those encoding pro-inflammatory cytokines and chemokines, such as IL-11, CXCL8,  
197 and LIF, were among the most downregulated genes in YAP<sup>-/-</sup> infected cells compared to WT  
198 infected cells (**Figure 3B**). In a few upregulated genes in YAP<sup>-/-</sup> infected cells compared to  
199 WT infected cells, we detected lysosomal genes such as *LAMP1*, *NPC2*, and *GBA* (**Figure**  
200 **3B**). In YAP<sup>-/-</sup> cells, we found an upregulation of the lysosome pathway and a downregulation  
201 of the autophagic pathway (**Figure 3A**), which are known to reduce the intracellular  
202 replication of *S. aureus*. Altogether, these results indicate the involvement of YAP in host  
203 response gene expression and its contribution to transcriptional immune response in  
204 HEK293 cells, consistent with the gene expression profile induced by *S. aureus* infection.

205

#### 206 **YAP/TEAD transcriptional activity regulate autophagic flux and lysosomal acidification**

207 We then decided to focus on the modulation of autophagy and lysosome signaling pathways  
208 by YAP activity in non-infected conditions since these processes are critical for defense  
209 against intracellular bacteria. In our model, the overall increase in the lysosome signaling  
210 pathway in YAP<sup>-/-</sup> cells was mainly due to an increased expression of genes encoding  
211 lysosomal membrane proteins, which could be used as lysosome markers (e.g., *LAMP1*,  
212 *NPC2*, and *GBA*) (**Figure 4A**). In contrast, we found decreased expression of several genes  
213 related to lysosomal functions. Indeed, we found a decrease in the expression of the *AP1S2*  
214 and *AP1G1* genes encoding adaptins that are involved in lysosomal enzyme transport from  
215 the trans-Golgi network to lysosomes<sup>37</sup>. Furthermore, we observed a downregulation in the  
216 expression of cathepsin L (*CTSL*) and W and an upregulation in the expression of cathepsin  
217 A and Z. A previous study has shown that *CTSL* inhibition leads to LC3-II accumulation and  
218 lysosomal enlargement in macrophages<sup>38</sup>. In addition, we found that *ATP6V0D1*, a gene  
219 encoding a subunit of the V-ATPase lysosomal pump critical for lysosomal acidification and  
220 autophagy<sup>39</sup>, was downregulated in YAP<sup>-/-</sup> cells (**Figure 4A and S. Figure 4A**). Interestingly,

221 a chromatin immunoprecipitation assay using next-generation sequencing (ChIP-seq) data  
222 from previous reports <sup>40</sup> revealed YAP/TAZ/TEAD peaks at active enhancer sites of the  
223 *ATP6V0D1*, *ATP6V0A1*, *ATP6V1C1*, and *ATP6V0B* genes <sup>40</sup>. Thus, this transcriptional  
224 profile indicates potential lysosome defects in *YAP*<sup>-/-</sup> cells that are modulated by YAP/TEAD  
225 transcriptional activity. In addition, several autophagy-related genes, including *MAP1LC3A*  
226 (encoding microtubule-associated protein 1 light chain 3 alpha (LC3A) protein), *ATG12*  
227 (involved in autophagosome elongation through the LC3-I to LC3-II lipidation), and *ATG13*  
228 (involved in autophagosome formation), were downregulated. In addition, we observed an  
229 upregulation in *ATG10* (involved in the formation of the ATG5-ATG12-ATG16L elongation  
230 complex) that probably compensates for *ATG12* downregulation (**Figure 4A and S. Figure**  
231 **4A**). This profile argued for default autophagosome formation and elongation in *YAP*<sup>-/-</sup> cells.  
232 Given that YAP/TAZ control the expression of actin-related tension proteins MLC2 and  
233 DIAPH1, which are important for autophagosome formation <sup>14</sup>, we assessed the expression  
234 of these two genes; however, MLC2 expression was not detected in HEK293 cells and  
235 DIAPH1 expression was similar in HEK293 WT and *YAP*<sup>-/-</sup> cells (data not shown).  
236 To confirm the findings of the transcriptional analysis, we monitored autophagic flux in WT,  
237 *YAP*<sup>-/-</sup>, and *YAPΔTEAD*<sup>+/+</sup> cells. The immunoblotting assay showed a decrease in the LC3-I  
238 total protein level in *YAP*<sup>-/-</sup> cells, corroborating the transcriptomic results (**Figure 4BC**).  
239 Moreover, the decrease in LC3-I was associated with a decrease in the LC3-II total level,  
240 without a change in the LC3-II/LC3-I ratio, suggesting that LC3 lipidation was retained  
241 (**Figure 4BC**). To further study autophagy regulation in both models, we used live-cell  
242 confocal microscopy and a CytolD probe to label autophagic vesicles in living cells.  
243 Autophagic vesicles were more abundant and especially much larger in *YAP*<sup>-/-</sup> and  
244 *YAPΔTEAD*<sup>+/+</sup> cells than in WT cells (**Figure 4DE**). In *YAP*-mutated cells, these larger  
245 autophagic vesicles also appeared misshapen, in contrast to the spherical vesicles observed  
246 in WT cells (**Figure 4D**). Similar results were obtained from cells immunolabeled with anti-  
247 LC3 antibody (**Figure 4F**), ruling out an artifact due to CytolD. Together, these results reflect  
248 autophagic flux reduction resulting in the accumulation of large autophagic vesicles, which

249 suggests an anomaly in the degradative activity of autophagolysosomes. For instance,  
250 lysosomal alkalinization is known to induce the accumulation of autophagic vesicles and  
251 larger autophagolysosomes<sup>39</sup>. Since our transcriptomic results indicate possible defects in  
252 lysosomal acidification, we tested lysosomal acidity in YAP-mutated cells. No difference was  
253 detected in basal conditions between WT, YAP<sup>-/-</sup>, and YAPΔTEAD<sup>-/+</sup> cells. Bafilomycin A1, an  
254 inhibitor of the V-ATPase pump, was effective in inducing lysosomal alkalinization in both cell  
255 lines (**Figure 4GH**). However, 20 min after bafilomycin A1 removal, lysosomes reacidification  
256 was more efficient in WT cells than in YAP<sup>-/-</sup> and YAPΔTEAD<sup>-/+</sup> cells, indicating lysosomal  
257 dysfunction in these cells (**Figure 4GH**). These results showed that YAP/TEAD activity  
258 promotes the expression of autophagic and lysosomal genes that are important for normal  
259 autophagic flux regulation and lysosomal acidification.

260

### 261 **Loss of YAP/TEAD transcriptional activity worsens blockage of autophagic flux** 262 **induced by *S. aureus* and fosters its escape from autophagic vesicles**

263 Internalized *S. aureus* is known to elicit a strong autophagic response in NPPCs, which is  
264 required to clear intracellular *S. aureus* by addressing *S. aureus*-containing autophagosomes  
265 to lysosomes. Therefore, we decided to investigate how the alteration of autophagy and  
266 lysosome signaling pathways observed in YAP-mutated cells could explain the strong  
267 replication of intracellular *S. aureus* in these cells.

268 Transcriptomic analysis of WT and YAP<sup>-/-</sup> cells infected with *S. aureus* showed that the  
269 expression of specific genes involved in autophagy and lysosome signaling pathways were  
270 altered in YAP<sup>-/-</sup> cells (**S. Figure 3AB**). For instance, *CTSL* expression was still lower in YAP<sup>-/-</sup>  
271 <sup>-/-</sup> infected cells compare to WT infected cells (**S. Figure 3A-C**).

272 Live-cell confocal microscopy was used to quantify the number and volume of autophagic  
273 vesicles. In WT cells, we observed a strong increase in autophagic vesicle count and volume  
274 at 3 hpi, whereas at 7 hpi, the volume of autophagic vesicles continued to rise with no further  
275 increase in the vesicle count, which is in favor of the blockage of autophagic flux (**Figure 5A-**  
276 **C**). Interestingly, in WT cells, the colocalization of *S. aureus* with autophagic vesicles was

277 found to decrease between 3 and 7 hpi (**S. Figure 4A and Figure 5D**), which reflects the  
278 ability of *S. aureus* to escape from autophagic vesicles (e.g., autophagosomes or  
279 autolysosomes). In some of the WT cells, we also observed disrupted *S. aureus* and diffused  
280 red fluorescence within autophagic vesicles, indicating that the degradative function of  
281 autophagolysosomes can limit the intracellular replication of *S. aureus* in WT cells (**Figure**  
282 **5A**). In contrast, such a pattern of degradation was not observed in YAP<sup>-/-</sup> and YAPΔTEAD<sup>-/+</sup>  
283 cells, suggesting that lysosomal degradative function is altered in these cells, which is in  
284 accordance with our data of transcriptomic and LysoSensor analyses.

285 This statement is also supported by the fact that the colocalization of *S. aureus* with  
286 autophagic vesicles at 7 hpi in these cells was lower than that observed in WT cells (**Figure**  
287 **5A, D, and S. Figure 4A**), which reflected *S. aureus* escape from autophagic vesicles. This  
288 result did not seem to be due to a defect in autophagy initiation since the autophagic vesicle  
289 count increased at 3 hpi compared to non-infected conditions, as it did for WT cells (**Figure**  
290 **5AB and S. Figure 4AB**). It is also noteworthy that even if the level of colocalization of *S.*  
291 *aureus* with autophagic vesicles was identical to that of WT cells at 3 hpi in YAP-mutated  
292 cells, the autophagic vesicles surrounding *S. aureus* were unusually distorted as compared  
293 to the spherical vesicles surrounding each individual *S. aureus* bacterium in WT cells (**Figure**  
294 **5A, D, and S. Figure 4A**). More importantly, the volume of autophagic vesicles strongly  
295 increased at 3 hpi in YAP<sup>-/-</sup> cells than in WT infected cells (**Figure 5A, C**), indicating a further  
296 autophagic flux blockage during *S. aureus* infection. In YAPΔTEAD<sup>-/+</sup> cells, the vesicle  
297 volume did not increase further at 3 hpi (**S. Figure 4B, C**), which could be explained by the  
298 fact that the vesicle volume in uninfected cells was already higher than that in WT and YAP<sup>-/-</sup>  
299 cells. For YAP-mutated cell lines, vesicle count and volume decreased between 3 and 7 hpi,  
300 which seems to be due to the disruption of autophagic vesicles by *S. aureus* that did not  
301 colocalize with the spherical vesicles but were surrounded by CytoID-labeled residues  
302 (**Figure 5AC and S. Figure 4AC**). Immunoblots showed that the LC3-II/LC3-I ratio was  
303 higher during infection in YAP<sup>-/-</sup> cells compared to WT cells, corroborating that *S. aureus*  
304 takes advantage of YAP-deficient cells to further inhibit autophagic flux (**Figure 5EF**).

305 We then performed similar experiments with WT cells infected with ST80 WT and ST80  
306  $\Delta edinB$  strains, both of which were found to enhance vesicle count and volume in a very  
307 similar manner (**S. Figure 5AC**). Although both ST80 WT and ST80 $\Delta EB$  strains were found  
308 to be highly colocalized in autophagic vesicles at 3 hpi, but the former was able to escape  
309 from autophagic vesicles at 7 hpi in contrast to the latter that remained more confined to  
310 autophagic vesicles (**S. Figure 5AB**).

311 Altogether, these results indicate that the alteration of autophagy and lysosome basal  
312 functions in YAP-mutated cells enables *S. aureus* to block autophagic flux more efficiently,  
313 as soon as 3 hpi, to escape from autophagic vesicles and avoid its clearance into  
314 degradative compartments at 7 hpi. These results can explain why *S. aureus* exhibits more  
315 pronounced replication in YAP-mutated cells after 3 hpi. In addition, we showed that EDIN-B-  
316 expressing *S. aureus* was able to inhibit YAP and was more efficient in escaping autophagy.

317

### 318 **YAP promotes inflammatory response during *S. aureus* infection**

319 Upon bacterial infection, the cell-autonomous immune response of non-specialized immune  
320 cells displays antimicrobial mechanisms<sup>16,17,41</sup>. An important part of this response is the  
321 activation of molecular signaling pathways that enable the expression of inflammatory  
322 mediators to attract specialized immune cells for bacterial clearance.

323 Our transcriptomic analysis highlighted that most of the differences in gene expression  
324 between YAP<sup>-/-</sup> and WT cells were related to inflammatory signaling pathways. Members of  
325 the IL-6, IL-11, and LIF signaling pathways were found to be enhanced during *S. aureus*  
326 infection in WT cells but remained downregulated in both infected and uninfected YAP<sup>-/-</sup> cells.  
327 These cytokines support the proliferation and differentiation of hematopoietic stem cells<sup>41</sup>,  
328 and LIF has been shown to enhance the killing of *S. aureus* by neutrophils<sup>42</sup>. Although *IL6*  
329 was expressed at low levels in the nCounter panel, RT-qPCR showed that *IL6* expression  
330 was low in HEK293 cells but was nevertheless increased during *S. aureus* infection in WT  
331 cells and remained lower in both infected and uninfected YAP<sup>-/-</sup> cells (**Figure 6C**). The  
332 expression of chemokine genes, including *CXCL8*, *CCL20*, *CXCL2*, and *CXCL1*, which are

333 known to enhance immune cell recruitment and are consequently involved in *the S. aureus*  
334 inflammatory response, especially CXCL8, which is critical for neutrophil recruitment <sup>43,44</sup>,  
335 was enhanced during *S. aureus* infection in WT cells. Even if these genes were upregulated  
336 during *S. aureus* infection in YAP<sup>-/-</sup> cells, the expression of these genes remained strongly  
337 downregulated in YAP<sup>-/-</sup> cells compared to WT cells (**Figure 6AB**). Moreover, *S. aureus*  
338 infection enhanced the expression of *PTGS2* (also known as cyclooxygenase-2) (**Figure**  
339 **6AB**), which encodes a key enzyme for the synthesis of prostaglandins that are involved in  
340 the inflammatory response against *S. aureus* <sup>45</sup>; however, *PTGS2* expression remained lower  
341 in YAP<sup>-/-</sup> infected and uninfected cells than in WT infected and uninfected cells (**Figure 6AB**).  
342 The inflammasome response is important during *S. aureus* infection for neutrophil  
343 recruitment <sup>46</sup>. We found that several inflammasome-related genes, such as *CASP4* and  
344 *NLRC4*, were downregulated in YAP<sup>-/-</sup> infected and uninfected cells. In addition, using RT-  
345 qPCR detect the low-level expression of *IL1B* was detected in WT cells during infection,  
346 whereas it remained undetectable in YAP<sup>-/-</sup> infected and uninfected cells (**Figure 6C**).  
347 Although YAP/TEAD itself could contribute to the expression of cytokines and chemokines,  
348 we found that the expression of some transcription factors involved in inflammation was  
349 modified in YAP<sup>-/-</sup> cells. During infection, nuclear factor κB (NF-κB) and activator protein 1  
350 (AP-1) are known to trigger the first inflammatory response in cells <sup>47</sup>. Our results confirmed  
351 that *S. aureus* infection triggers NF-κB pathway-related genes but does not increase NF-κB  
352 subunits (**S. Figure 6AB**). Likewise, we showed that *S. aureus* infection upregulates MAPK  
353 pathway-related genes with increased expression of AP1 members *JUNB* and *FOS* (**S.**  
354 **Figure 6AB**). However, in YAP<sup>-/-</sup> control or infected cells, we found that these two pathways  
355 were highly disrupted due to the downregulation of genes encoding NF-κB subunits (*NFKB1*,  
356 *NFKB2*, *REL*, *RELA*, and *RELB*) and AP1 members, including *JUN*, *JUNB*, and *FOS* (**S.**  
357 **Figure 6A-B**). Of note, several other inflammatory pathways were altered in YAP<sup>-/-</sup> cells, with  
358 a reduction in interferon signaling, NLR signaling, DNA sensing, and MHC class I signaling  
359 (**Figure 3A**). Altogether, these results highlight that YAP activity can modulate the

360 expression of a wide range of inflammation-related genes involved in the response against *S.*  
361 *aureus*.

362

### 363 ***S. aureus* ST80 infection in synovial organoids also modulates YAP signaling**

364 Organoid-based infection models enable the study of infection in a 3D cell model using  
365 primary cells that display more physiological characteristics than continuous cell lines. In this  
366 experiment, we used a model of synovial organoids<sup>36</sup>, formed with fibroblast-like  
367 synoviocytes (FLSs) from three different donors that were infected with ST80 strains. Given  
368 that *S. aureus* is one of the leading causes of osteoarticular infection in humans (Tong et al.,  
369 2015), this infection model should be highly clinically relevant.

370 Live-cell confocal microscopy showed that *S. aureus* was internalized in FLS and replicated  
371 in these cells (**Figure 7A**). We found that the EDIN-B-expressing ST80 WT strain thoroughly  
372 altered the organization of the actin cytoskeleton as early as 30 min post-infection and  
373 prevented the formation of actin fibers, whereas actin fibers were neither disrupted nor  
374 hindered by the ST80  $\Delta edinB$  strain (**Figure 7A**), which reflects the ability of EDIN-B to  
375 inhibit RhoA.

376 In this model of synovial organoids, FLS forms a lining layer at the edge of the organoid, and  
377 more sparse cells in the core of the structure are organized like a stroma mimicking the  
378 human synovial membrane<sup>36</sup> (**Figure 7B**). Synovial lining layer thickening, which is  
379 recognized as a hallmark of synovial inflammation, was found to be mediated through YAP  
380 activity<sup>36,49,50</sup>. At 7 hpi, ST80  $\Delta edinB$  induced synovial lining layer thickening (**Figure 7B-D**)  
381 which suggest that YAP is activated. In contrast, ST80 WT that expressed EDIN-B did not  
382 induce an increase in of the synovial lining layer thickness (**Figure 7B-D**), probably reflecting  
383 YAP inhibition. This assumption was strengthened by the confocal microscopy images  
384 showing that the EDIN-B-expressing ST80 WT strain, unlike the ST80  $\Delta edinB$  strain, was  
385 able to reduce YAP immunolabeling in infected synovial lining layer cells at 7 hpi (**Figure**  
386 **7E**). In addition, the ST80 WT strain was found to inhibit YAP transcriptional activity by  
387 reducing the expression of the connective tissue growth factor (*CTGF*) and *CYR61* genes,



388 whereas the ST80  $\Delta edinB$  strain increased their expression (**Figure 7F**), which confirmed  
389 that the EDIN-B-expressing ST80 WT strain was able to inhibit YAP transcriptional activity in  
390 synovial organoids. In addition, since the *CXCL8* and *PTGS2* genes were downregulated in  
391 HEK293 YAP<sup>-/-</sup> infected cells compared to WT infected cells, we assessed the expression of  
392 these two genes in synovial organoids. Compared to uninfected organoids, ST80  $\Delta edinB$   
393 induced an increase in the expression of *CXCL8* and *PTGS2*, in contrast to the EDIN-B-  
394 expressing ST80 WT strain, which was consistent with YAP transcriptional activity inhibition  
395 in HEK293 cells.

396 In conclusion, this organoid-based model confirmed the strong ability of the EDIN-B-  
397 expressing ST80 WT strain to inhibit YAP transcriptional activity and reduce the expression  
398 of inflammatory mediators. These results suggest that YAP inhibition by EDIN-B can reduce  
399 synovial inflammation and prevent immune cell recruitment at the infection site.

400

## 401 **DISCUSSION**

402 In this study, we sought to investigate whether YAP is involved in the clearance of  
403 intracellular *S. aureus*. We demonstrated that YAP plays a critical role in efficient cell-  
404 autonomous immune response against intracellular *S. aureus* by controlling autophagy-  
405 lysosome and inflammation-related signaling pathways.

406 Our results are consistent with the role of YAP/TAZ transcriptional activity in promoting  
407 autophagy<sup>14,15,51</sup>. In our model of YAP-mutated cells, we found no differences in *MLC2* and  
408 *DIAPH1* expression, which is important for autophagosome formation<sup>14</sup>. In contrast, we  
409 observed alterations in the late phase of autophagy, which is consistent with a previous study  
410 showing impaired fusion between autophagosomes and lysosomes<sup>15</sup>, but the mechanism  
411 involved seems to be different. Indeed, we observed abnormal and oversized autophagic  
412 vesicles. In particular, we found that YAP<sup>-/-</sup> cells have an alteration in lysosomal acidification,  
413 which can be explained by the decreased expression of *ATP6V0D1*, which encodes a V-  
414 ATPase subunit required for lysosomal acidification<sup>52</sup>. Moreover, abnormal and oversized  
415 autophagolysosomes with poor degradative functionality have been described in cells

416 deficient for V-ATPase subunits<sup>39</sup>, which supports our findings. In addition, we found that  
417 *CTSL* was downregulated in the *YAP*<sup>-/-</sup> HEK293 cells. It has been shown that *CTSL*-deleted  
418 cells have important lysosomal dysfunction and LC3-II accumulation, reflecting an altered  
419 autophagic flux<sup>38</sup>. In addition, we showed that this effect was mediated by the YAP TEAD  
420 binding domain, since *YAP* $\Delta$ TEAD<sup>+/-</sup> cells display autophagic defects similar to those of *YAP*<sup>-/-</sup>  
421 cells. However, we cannot exclude the possibility that YAP interacts through its TEAD-  
422 binding domain with another transcription factor involved in autophagy and lysosome  
423 signaling pathways. Indeed, a recent study showed that YAP can interact with transcription  
424 factor EB (TFEB) to induce the expression of autophagic and lysosomal genes<sup>51</sup> but whether  
425 the TEAD-binding domain of YAP is required for its interaction with TFEB is unknown. Thus,  
426 YAP/TEAD and/or YAP/TFEB could act synergistically for autophagy-and lysosome-related  
427 gene regulation. Overall, our data reinforce the role of YAP in autophagy regulation and  
428 provide new insights into how YAP promotes autophagic flux.

429 Our work shows that YAP transcriptional activity is required to control the replication of *S.*  
430 *aureus*, and that some EDIN-B-expressing *S. aureus* strains can inhibit YAP to promote their  
431 own intracellular replication. Given that autophagy is clearly established as a major  
432 mechanism for clearing *S. aureus in vitro* and *in vivo*<sup>31-33</sup>, the autophagy dysfunction  
433 observed in YAP-mutated cells in this study could explain why *S. aureus* infection was more  
434 pronounced when YAP transcriptional activity was inhibited or absent. The altered lysosomal  
435 function observed in YAP-mutated cells may also decrease *S. aureus* clearance as *CTSL*-  
436 deficient macrophages exhibit a poor ability to remove intracellular *S. aureus*<sup>53</sup>, and genetic  
437 manipulations of V-ATPases or bafilomycinA1 treatment in macrophages promoted *S.*  
438 *aureus* intracellular replication<sup>54</sup>. However, to avoid degradation, *S. aureus* has also been  
439 found to inhibit the fusion of autophagosomes with lysosomes and escape from autophagic  
440 vesicles to replicate inside the cytosol<sup>31</sup>. In our model, the loss of YAP transcriptional  
441 activity, which induces the blockage of autophagic flux, was found to promote  
442 autophagosome escape and replication of *S. aureus*.

443 In addition, we found that EDIN-B-expressing *S. aureus* inhibited YAP transcriptional activity,  
444 which enabled them to replicate more efficiently in the cells, likely by escaping from  
445 autophagic vesicles. Autophagy is a conserved cellular process known to be involved in the  
446 clearance of intracellular bacteria<sup>55</sup>, and RhoA-targeting toxins (such as EDINs) can be  
447 expressed by other pathogenic bacteria such as *Yersinia* and *Salmonella* species<sup>24,25</sup>. In  
448 addition, bacteria secreting RhoA targeting-toxins were found to alter actin dynamics, leading  
449 to the impairment of tight and adherent junctions and an increase in bacterial invasion across  
450 the epithelium and endothelium<sup>25,27</sup>. Interestingly, YAP is known to promote the formation of  
451 focal adhesion complex, and regulate actin dynamics, and be activated after intestinal barrier  
452 disruption following bacterial infection<sup>14,21,56</sup>. Thus, we speculated that some known RhoA  
453 inhibition mechanisms achieved by bacteria could be mediated by YAP activity.

454 Increasing evidence demonstrates that YAP/TEAD transcriptional activity can play a pro-  
455 inflammatory role by promoting the expression of pro-inflammatory mediators such as *IL6*<sup>12</sup>,  
456 *CCL2*<sup>57,58</sup>, *IL8*<sup>9</sup>, *IL1B*<sup>13</sup>, *PTGS2*<sup>59</sup>, and NF- $\kappa$ B family members<sup>60</sup>. However, contradictory  
457 results exist in the literature, indicating an anti-inflammatory role of YAP in mouse models  
458<sup>20,61,62</sup>. In our study, YAP transcriptional activity was found to have a pro-inflammatory effect  
459 in HEK293 cells. We found that the loss of YAP activity decreased the expression of several  
460 pro-inflammatory genes known to foster *S. aureus* clearance *in vivo*. Thus, RhoA-mediated  
461 inhibition of YAP by bacteria could be a way to evade the immune system by decreasing the  
462 inflammatory response.

463 Another important question is how bacteria modulate YAP activity in host cells. In contrast to  
464 our results, *S. aureus* infection in *Drosophila* was found to increase Yorkie cytoplasmic  
465 localization in fly fat bodies<sup>22</sup>. Yorkie overexpression in fly fat bodies was found to increase  
466 *S. aureus*-induced death compared to WT flies<sup>22</sup>. However, there are important differences  
467 between human NPPCs and fly fat bodies, which can influence YAP activity and its  
468 subcellular localization upon infection. In mice, several other bacterial species (e.g.,  
469 *Streptococcus pneumoniae* and *Helicobacter pylori*) lead to nuclear translocation<sup>18,20</sup>. Thus,  
470 it could be interesting to test whether YAP has an anti-*S. aureus* function in mouse models.

471 Although bacteria-induced tissue damage can promote YAP activation in mouse models, the  
472 mechanisms that induce nuclear translocation of YAP upon bacterial infection are not fully  
473 understood<sup>20,21</sup>. Our results showed that *S. aureus* supernatant alone is not sufficient to  
474 induce YAP nuclear translocation, which suggests that internalization of *S. aureus* is needed  
475 for inducing nuclear translocation of YAP. Interestingly, *S. aureus* internalization is mainly  
476 driven by  $\alpha 5\beta 1$  integrins, which trigger the activation of focal adhesion kinase (FAK)<sup>30</sup>. YAP  
477 is known to be highly sensitive to cell mechanical stimulation, such as integrin-FAK  
478 activation, which increases RhoA activity and causes YAP nuclear translocation<sup>63</sup>. Thus, it  
479 will be important to investigate whether YAP activation following *S. aureus* internalization  
480 could be a nonspecific “danger signal” by converting cell mechanical events into cell-  
481 autonomous immune responses, including xenophagy and inflammatory responses.  
482 Overall, this work provides new fundamental insights into the role of YAP in cell-autonomous  
483 immune responses. It also provides new insight into the role of the C3 exoenzyme EDIN  
484 during *S. aureus* infections. Thus, the findings of this work could help find new ways to fight  
485 intracellular bacteria and open the way for future microbiology and YAP-related  
486 investigations.

487 **REFERENCES**

488

- 489 1. Dong, J. *et al.* Elucidation of a Universal Size-Control Mechanism in *Drosophila* and  
490 Mammals. *Cell* **130**, 1120–1133 (2007).
- 491 2. Vassilev, A., Kaneko, K. J., Shu, H., Zhao, Y. & DePamphilis, M. L. TEAD/TEF  
492 transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein  
493 localized in the cytoplasm. *Genes Dev* **15**, 1229–1241 (2001).
- 494 3. Hilman, D. & Gat, U. The Evolutionary History of YAP and the Hippo/YAP Pathway.  
495 *Molecular Biology and Evolution* **28**, 2403–2417 (2011).
- 496 4. Li, Z. *et al.* Structural insights into the YAP and TEAD complex. *Genes Dev* **24**, 235–240  
497 (2010).
- 498 5. Liu, C.-Y. *et al.* The Hippo Tumor Pathway Promotes TAZ Degradation by  
499 Phosphorylating a Phosphodegron and Recruiting the SCF $\beta$ -TrCP E3 Ligase. *J Biol*  
500 *Chem* **285**, 37159–37169 (2010).
- 501 6. Zhao, B. *et al.* Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell  
502 contact inhibition and tissue growth control. *Genes Dev* **21**, 2747–2761 (2007).
- 503 7. Dupont, S. *et al.* Role of YAP/TAZ in mechanotransduction. *Nature* **474**, 179–183 (2011).
- 504 8. Aragona, M. *et al.* A Mechanical Checkpoint Controls Multicellular Growth through  
505 YAP/TAZ Regulation by Actin-Processing Factors. *Cell* **154**, 1047–1059 (2013).
- 506 9. Wang, L. *et al.* Integrin-YAP/TAZ-JNK cascade mediates atheroprotective effect of  
507 unidirectional shear flow. *Nature* (2016) doi:10.1038/nature20602.
- 508 10. Zanconato, F., Cordenonsi, M. & Piccolo, S. YAP/TAZ at the Roots of Cancer. *Cancer*  
509 *Cell* **29**, 783–803 (2016).
- 510 11. Geng, J. *et al.* The transcriptional coactivator TAZ regulates reciprocal differentiation of  
511 TH17 cells and Treg cells. *Nature Immunology* **18**, 800–812 (2017).
- 512 12. Taniguchi, K. *et al.* A gp130–Src–YAP module links inflammation to epithelial  
513 regeneration. *Nature* **519**, 57–62 (2015).

- 514 13. Zhou, X. *et al.* YAP Aggravates Inflammatory Bowel Disease by Regulating M1/M2  
515 Macrophage Polarization and Gut Microbial Homeostasis. *Cell Rep* **27**, 1176-1189.e5  
516 (2019).
- 517 14. Pavel, M. *et al.* Contact inhibition controls cell survival and proliferation via YAP/TAZ-  
518 autophagy axis. *Nat Commun* **9**, (2018).
- 519 15. Totaro, A. *et al.* Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZ  
520 mechanotransduction. *Proc Natl Acad Sci U S A* **116**, 17848–17857 (2019).
- 521 16. Krausgruber, T. *et al.* Structural cells are key regulators of organ-specific immune  
522 response. *Nature* **583**, 296–302 (2020).
- 523 17. Randow, F., MacMicking, J. D. & James, L. C. Cellular Self-Defense: How Cell-  
524 Autonomous Immunity Protects Against Pathogens. *Science* **340**,  
525 10.1126/science.1233028 (2013).
- 526 18. Wu, Y. *et al.* Helicobacter pylori-induced YAP1 nuclear translocation promotes gastric  
527 carcinogenesis by enhancing IL-1 $\beta$  expression. *Cancer Med* **8**, 3965–3980 (2019).
- 528 19. García-Gil, A. *et al.* SopB activates the Akt-YAP pathway to promote Salmonella survival  
529 within B cells. *Virulence* **9**, 1390–1402 (2018).
- 530 20. LaCanna, R. *et al.* Yap/Taz regulate alveolar regeneration and resolution of lung  
531 inflammation. *J Clin Invest* **129**, 2107–2122 (2019).
- 532 21. Ma, Y.-C. *et al.* YAP in epithelium senses gut barrier loss to deploy defenses against  
533 pathogens. *PLOS Pathogens* **16**, e1008766 (2020).
- 534 22. Liu, B. *et al.* Toll Receptor-Mediated Hippo Signaling Controls Innate Immunity in  
535 Drosophila. *Cell* **164**, 406–419 (2016).
- 536 23. Sugai, M., Chen, C. H. & Wu, H. C. Bacterial ADP-ribosyltransferase with a substrate  
537 specificity of the rho protein disassembles the Golgi apparatus in Vero cells and mimics  
538 the action of brefeldin A. *PNAS* **89**, 8903–8907 (1992).
- 539 24. Aktories, K. Bacterial protein toxins that modify host regulatory GTPases. *Nat Rev*  
540 *Microbiol* **9**, 487–498 (2011).

- 541 25. Lemichez, E. & Aktories, K. Hijacking of Rho GTPases during bacterial infection. *Exp*  
542 *Cell Res* **319**, 2329–2336 (2013).
- 543 26. Munro, P. *et al.* The Staphylococcus aureus epidermal cell differentiation inhibitor toxin  
544 promotes formation of infection foci in a mouse model of bacteremia. *Infect Immun* **78**,  
545 3404–3411 (2010).
- 546 27. Courjon, J. *et al.* EDIN-B Promotes the Translocation of Staphylococcus aureus to the  
547 Bloodstream in the Course of Pneumonia. *Toxins (Basel)* **7**, 4131–4142 (2015).
- 548 28. Munro, P. *et al.* High prevalence of edin-C encoding RhoA-targeting toxin in clinical  
549 isolates of Staphylococcus aureus. *Eur J Clin Microbiol Infect Dis* **30**, 965–972 (2011).
- 550 29. Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L. & Fowler, V. G.  
551 Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical  
552 Manifestations, and Management. *Clin Microbiol Rev* **28**, 603–661 (2015).
- 553 30. Josse, J., Laurent, F. & Diot, A. Staphylococcal Adhesion and Host Cell Invasion:  
554 Fibronectin-Binding and Other Mechanisms. *Front Microbiol* **8**, 2433 (2017).
- 555 31. Neumann, Y. *et al.* Intracellular Staphylococcus aureus eludes selective autophagy by  
556 activating a host cell kinase. *Autophagy* **12**, 2069–2084 (2016).
- 557 32. Gibson, J. F. *et al.* Neutrophils use selective autophagy receptor Sqstm1/p62 to target  
558 Staphylococcus aureus for degradation in vivo in zebrafish. *Autophagy* **17**, 1448–1457  
559 (2021).
- 560 33. Maurer, K. *et al.* Autophagy Mediates Tolerance to Staphylococcus aureus Alpha-Toxin.  
561 *Cell Host Microbe* **17**, 429–440 (2015).
- 562 34. Rigaiil, J. *et al.* Improved Enzyme Protection Assay to Study Staphylococcus aureus  
563 Internalization and Intracellular Efficacy of Antimicrobial Compounds. *J Vis Exp* (2021)  
564 doi:10.3791/62903.
- 565 35. Molinari, G. *et al.* Localization of the C3-Like ADP-Ribosyltransferase from  
566 Staphylococcus aureus during Bacterial Invasion of Mammalian Cells. *Infect Immun* **74**,  
567 3673–3677 (2006).

- 568 36. Caire, R. *et al.* YAP/TAZ: Key Players for Rheumatoid Arthritis Severity by Driving  
569 Fibroblast Like Synoviocytes Phenotype and Fibro-Inflammatory Response. *Frontiers in*  
570 *Immunology* **12**, 5232 (2021).
- 571 37. Hirst, J., Borner, G. H. H., Harbour, M. & Robinson, M. S. The aftiphilin/p200/gamma-  
572 synergin complex. *Mol Biol Cell* **16**, 2554–2565 (2005).
- 573 38. Jung, M., Lee, J., Seo, H.-Y., Lim, J. S. & Kim, E.-K. Cathepsin Inhibition-Induced  
574 Lysosomal Dysfunction Enhances Pancreatic Beta-Cell Apoptosis in High Glucose.  
575 *PLOS ONE* **10**, e0116972 (2015).
- 576 39. Mauvezin, C., Nagy, P., Juhász, G. & Neufeld, T. P. Autophagosome–lysosome fusion is  
577 independent of V-ATPase-mediated acidification. *Nat Commun* **6**, 7007 (2015).
- 578 40. Zanconato, F. *et al.* Genome-wide association between YAP/TAZ/TEAD and AP-1 at  
579 enhancers drives oncogenic growth. *Nature Cell Biology* **17**, 1218–1227 (2015).
- 580 41. West, N. R. Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. *Front*  
581 *Immunol* **10**, 1093 (2019).
- 582 42. Borish, L. & Rocklin, R. E. Effects of leukocyte inhibitory factor (LIF) on neutrophil  
583 phagocytosis and bactericidal activity. *J Immunol* **138**, 1475–1479 (1987).
- 584 43. Chensue, S. W. Molecular Machinations: Chemokine Signals in Host-Pathogen  
585 Interactions. *Clin Microbiol Rev* **14**, 821–835 (2001).
- 586 44. Reyes-Robles, T. *et al.* Staphylococcus aureus Leukotoxin ED Targets The Chemokine  
587 Receptors CXCR1 and CXCR2 to Kill Leukocytes and Promote Infection. *Cell Host*  
588 *Microbe* **14**, 10.1016/j.chom.2013.09.005 (2013).
- 589 45. Bernard, J. J. & Gallo, R. L. Cyclooxygenase-2 Enhances Antimicrobial Peptide  
590 Expression and Killing of Staphylococcus aureus. *J Immunol* **185**, 6535–6544 (2010).
- 591 46. Miller, L. S. *et al.* MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2  
592 activation in immunity against Staphylococcus aureus. *Immunity* **24**, 79–91 (2006).
- 593 47. Barton, G. M. A calculated response: control of inflammation by the innate immune  
594 system. *J Clin Invest* **118**, 413–420 (2008).



- 595 48. Josse, J., Velard, F. & Gangloff, S. C. Staphylococcus aureus vs. Osteoblast:  
596 Relationship and Consequences in Osteomyelitis. *Front Cell Infect Microbiol* **5**, 85  
597 (2015).
- 598 49. Roelofs, A. J. *et al.* Joint morphogenetic cells in the adult mammalian synovium. *Nature*  
599 *Communications* **8**, 15040 (2017).
- 600 50. Symons, R. A. *et al.* Targeting the IL-6–Yap–Snail signalling axis in synovial fibroblasts  
601 ameliorates inflammatory arthritis. *Annals of the Rheumatic Diseases* **81**, 214–224  
602 (2022).
- 603 51. Ikeda, S. *et al.* YAP plays a crucial role in the development of cardiomyopathy in  
604 lysosomal storage diseases. *J Clin Invest* **131**, (2021).
- 605 52. Xia, Y. *et al.* The macrophage-specific V-ATPase subunit ATP6V0D2 restricts  
606 inflammasome activation and bacterial infection by facilitating autophagosome-lysosome  
607 fusion. *Autophagy* **15**, 960–975 (2019).
- 608 53. Müller, S. *et al.* The endolysosomal cysteine cathepsins L and K are involved in  
609 macrophage-mediated clearance of Staphylococcus aureus and the concomitant  
610 cytokine induction. *The FASEB Journal* **28**, 162–175 (2014).
- 611 54. Geng, N. *et al.* Staphylococcus aureus Avoids Autophagy Clearance of Bovine Mammary  
612 Epithelial Cells by Impairing Lysosomal Function. *Front Immunol* **11**, 746 (2020).
- 613 55. Cong, Y., Dinesh Kumar, N., Mauthe, M., Verlhac, P. & Reggiori, F. Manipulation of  
614 selective macroautophagy by pathogens at a glance. *Journal of Cell Science* **133**,  
615 (2020).
- 616 56. Nardone, G. *et al.* YAP regulates cell mechanics by controlling focal adhesion assembly.  
617 *Nat Commun* **8**, (2017).
- 618 57. Liu, M. *et al.* Macrophage K63-Linked Ubiquitination of YAP Promotes Its Nuclear  
619 Localization and Exacerbates Atherosclerosis. *Cell Reports* **32**, 107990 (2020).
- 620 58. Kim, W. *et al.* Hepatic Hippo signaling inhibits pro-tumoral microenvironment to suppress  
621 hepatocellular carcinoma. *Gut* **67**, 1692–1703 (2018).

- 622 59. Li, W. *et al.* YAP transcriptionally regulates COX-2 expression and GCCS<sub>ysm-4</sub> (G-4), a  
623 dual YAP/COX-2 inhibitor, overcomes drug resistance in colorectal cancer. *Journal of*  
624 *Experimental & Clinical Cancer Research* **36**, 144 (2017).
- 625 60. Wang, Q. *et al.* REGγ Controls Hippo Signaling and Reciprocal NF-κB–YAP Regulation  
626 to Promote Colon Cancer. *Clin Cancer Res* **24**, 2015–2025 (2018).
- 627 61. Deng, Y. *et al.* Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic  
628 cartilage degradation. *Nat Commun* **9**, (2018).
- 629 62. Lv, Y. *et al.* YAP Controls Endothelial Activation and Vascular Inflammation Through  
630 TRAF6. *Circ Res* **123**, 43–56 (2018).
- 631 63. Elbediwy, A. *et al.* Integrin signalling regulates YAP and TAZ to control skin homeostasis.  
632 *Development* **143**, 1674–1687 (2016).
- 633 64. Herbert, S. *et al.* Repair of global regulators in *Staphylococcus aureus* 8325 and  
634 comparative analysis with other clinical isolates. *Infect. Immun.* **78**, 2877–2889 (2010).
- 635 65. Perret, M. *et al.* Cross-talk between *Staphylococcus aureus* leukocidins-intoxicated  
636 macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-  
637 dependent manner. *Cell Microbiol* **14**, 1019–1036 (2012).
- 638 66. Jones, C. L. & Khan, S. A. Nucleotide sequence of the enterotoxin B gene from  
639 *Staphylococcus aureus*. *J. Bacteriol.* **166**, 29–33 (1986).
- 640 67. Kiener, H. P., Lee, D. M., Agarwal, S. K. & Brenner, M. B. Cadherin-11 Induces  
641 Rheumatoid Arthritis Fibroblast-Like Synoviocytes to Form Lining Layers in Vitro. *The*  
642 *American Journal of Pathology* **168**, 1486–1499 (2006).
- 643

644 **Methods**

645

646 **Cell culture**

647 HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma-Aldrich,  
648 St. Louis, MO, USA) with 10% fetal bovine serum (FBS), 1% non-essential amino acid  
649 solution, and 1% penicillin and streptomycin (PS) solution. The plates were coated with  
650 fibronectin (1:100, Sigma-Aldrich, F1141) for 2 h at 37 °C before use. HEK293 cells were  
651 grown at different cell densities: For low density (LD) cell culture, cells were seeded at  
652 10,000 cells/cm<sup>2</sup> and used 24 h after seeding; for medium density (MD) cell culture, cells  
653 were seeded at 100,000 cells/cm<sup>2</sup> and used 24 h after seeding; for high density (HD) cell  
654 culture, cells were seeded at 100,000 cells/cm<sup>2</sup> and used 72 h after seeding.

655

656 **Cell line generation using CRISPR-Cas9 technology**

657 HEK293 YAP<sup>-/-</sup> were generated using commercially available plasmids with specific CRISPR-  
658 Cas-9 single guide RNA (sgRNA) and sequence for homology-directed repair targeting YAP  
659 sequence (Santa Cruz Biotechnology, Dallas, TX, USA) as previously reported<sup>36</sup>. HEK293  
660 YAP $\Delta$ TEAD<sup>+/+</sup> cells were generated using the CRISPR-Cas9 technique and homology-  
661 directed repair. sgRNA was designed to cut in exon 1 of the YAP gene at proline 98 using  
662 the following protospacer: 5'-CGACTCCTTCTTCAAGCCGC-3'. Homologous recombination  
663 was supported by a donor plasmid with a 5' homology arm of 681 bp, a 3' homology arm of  
664 837+12 bp, whose original sequence TTCAAGCCGCCG was modified by the sequence  
665 AGAAGAAGAAGA that introduced the following mutations: Phe96Arg, Lys97Arg, Pro98Arg,  
666 and Pro99Arg. CRISPR-Cas9 and donor plasmids were manufactured on demand by  
667 VectorBuilder (VectorBuilder, Neu-Isenburg, Germany). HEK293 cells were transfected with  
668 0.5  $\mu$ g of each plasmid and 2  $\mu$ L transfection reagent (Jet prime, Polyplus transfection, New  
669 York, NY, USA) in a final volume of 100  $\mu$ L. After 48 h of transfection, the cells were seeded  
670 at one cell per well in a 96-well plate for monoclonal expansion. Mutations following

671 homologous recombination were confirmed by PCR sequencing (Eurofins Genomics,  
672 Nantes, France).

673

#### 674 **Bacterial strains and plasmids**

675 *Staphylococcus aureus* strains used in the study were the HG001 strain, which is a  
676 methicillin-susceptible *S. aureus* (MSSA) strain that lacks *edin* genes<sup>64</sup> and the LUG1799  
677 strain, which is a minimally passaged strain belonging to the European lineage community-  
678 acquired methicillin-resistant *S. aureus* (CA-MRSA) ST80-MRSA-IV strain<sup>65</sup> and is referred  
679 to as ST80 wild-type (WT) and its isogenic *edinB* mutant that is referred to as ST80  $\Delta$ *edinB*  
680<sup>27</sup>. All strains were stored at  $-20^{\circ}\text{C}$  in cryotubes.

681 For live cell imaging, the plasmid pSK265, a derivative of pC194<sup>66</sup>, was used to express the  
682 *DsRed* gene under the control of the *rpob* promoter in *S. aureus* strains. All strains were  
683 transformed with the plasmid pSK265::*DsRed* by electroporation (Gene Pulser, Bio-Rad) and  
684 were grown at  $37^{\circ}\text{C}$  on blood agar (43049, Biomérieux) or tryptic soy agar (TSA) (920241,  
685 Becton Dickinson) supplemented with  $20\ \mu\text{g}/\text{mL}$  of chloramphenicol when appropriate.

686

#### 687 **Organoid culture and processing**

688 Synovial organoids were assembled as previously described<sup>67</sup> with modifications<sup>36</sup>.  
689 Fibroblast-like synoviocytes (FLS) were collected from osteoarthritis (OA) patients who  
690 provided written consent after oral information (IRB # 2014-A01688-39). FLS were mixed in  
691 phenol red-free Matrigel (356237, Corning, Corning, NY, USA) at  $4 \times 10^6$  cells/mL, and a  
692 single  $22\ \mu\text{L}$  droplet (representing approximately 90,000 cells) was added to each well of a  
693 96-well U-shaped very low-attachment surface plate (CLS4515, Corning). The plate was  
694 incubated at  $37^{\circ}\text{C}$  in  $5\% \text{CO}_2$  for 45 min to allow droplet gelation. Wells containing solidified  
695 droplets were filled with  $200\ \mu\text{L}$  of DMEM high-glucose medium supplemented with 10%  
696 FBS, 1 % glutamine, 1 % nonessential amino acids, 1 % PS, 0.1 mM ascorbic acid, and  
697 insulin (10  $\mu\text{g}/\text{mL}$ )-transferrin (10  $\mu\text{g}/\text{mL}$ )-selenium ( $3 \times 10^{-8}$  M) solution at  $37^{\circ}\text{C}$  in  $5\% \text{CO}_2$  for  
698 21 days. At day 21, organoids were fixed with glyoxal solution at pH 4.5 (e.g., for 500 mL:

699 355 mL ddH<sub>2</sub>O, 99 mL ethanol, 39 mL glyoxal (128465, Sigma-Aldrich), and 1 mL acetic  
700 acid) for 1 h at room temperature (RT) because PFA fixation was deleterious. Organoids  
701 were embedded in a gelatin 100G (7.5%)-sucrose (10%) solution and frozen in an  
702 isopentane bath at -50 °C for 2 min before storage at -80 °C.

703

#### 704 **Bacterial infection of HEK293 cells and organoids**

705 HEK293 cells and organoids were infected with *S. aureus* using the enzyme protection assay  
706 (EPA) technique as previously described<sup>34</sup>. Briefly, *S. aureus* bacterial suspensions were  
707 adjusted to an OD<sub>600</sub> of 0.5 and serially diluted in the culture media of HEK293 cells or  
708 organoids. HEK293 cells were infected at a multiplicity of infection (MOI) of 1 (or 10 if  
709 indicated) for 2 h at 37 °C and 5% CO<sub>2</sub>. Organoids were infected with 1×10<sup>8</sup> *S. aureus* per  
710 well in 24-well plates for 2 h at 37 °C and 5% CO<sub>2</sub> with gentle agitation. After incubation,  
711 media was replaced with fresh culture media supplemented with 10 µg/mL lysostaphin  
712 (Ambicin, Ambi Products, Lawrence, NY, USA) to kill extracellular *S. aureus*. Bacterial  
713 suspensions used for infection challenges were seeded on agar plates and quantified after a  
714 24-h incubation period to verify the real bacterial concentration. To quantify the intracellular  
715 load of *S. aureus* by culture, HEK293 cells were washed with phosphate buffered saline  
716 (PBS) to remove lysostaphin. Cells were lysed by osmotic shock using lysis buffer containing  
717 0.25% Triton X-100 (Sigma-Aldrich), 0.25X trypsin-EDTA (Sigma-Aldrich), and sterile  
718 water. The *S. aureus* load of cell lysates was quantified on an agar plate using an automatic  
719 plate seeder (EasySpiral Dilute, Interscience, St-Nom la Bretèche, France) and a colony  
720 counter (Scan 4000, Interscience).

721

#### 722 **Immunofluorescence**

723 HEK293 cells were fixed with 4% PFA at RT for 20 min or in ice-cold methanol for 15 min (for  
724 LC3A/B immunolabeling). Fixed and frozen organoids were cryosectioned to a thickness of  
725 30 µm. Samples (cells or cryosections) were rehydrated in PBS for 10 min and permeabilized  
726 in 0.3% Triton X-100 for 15 min. The samples were then incubated in blocking buffer

727 containing 1% BSA, 5% goat serum, and 0.1% Triton-X100 for 60 min at RT. Subsequently,  
728 the samples were incubated with the primary antibody or isotypic control diluted in blocking  
729 buffer overnight at 4 °C. The antibodies used were mouse IgG anti-YAP antibody (63.7 sc-  
730 101199, Santa Cruz Biotechnology; 1:100), rabbit anti-LC3A/B antibody (4108, Cell Signaling  
731 Technology, Leiden, The Netherlands), mouse and rabbit IgG isotype antibody (31903 and  
732 31235, Thermo Fisher Scientific; used at the same concentration as YAP or LC3A/B  
733 antibodies). After washing, the cells were incubated with secondary antibody, goat anti-  
734 mouse 488 or goat anti-rabbit 488 diluted in blocking buffer (A11034 and A32731, Thermo  
735 Fisher; 1:400) for 75 min at RT. The cells were counterstained with 4',6-diamidino-2-  
736 phenylindole (DAPI) for 10 min at 37 °C with or without dye-labeled phalloidin (ab176753 or  
737 ab176759, Abcam, Cambridge, UK) for 1 h at 37 °C. For LC3 immunolabeling (ref, Cell  
738 Signaling Technology, Leiden, The Netherlands), the cells were fixed with ice-cold methanol  
739 for 15 min, and the immunolabeling procedure was identical to YAP immunolabeling.

740

#### 741 **Live-cell confocal microscopy of HEK293 cells or organoids**

742 Cells and organoids were infected with DsRed-expressing *S. aureus* strains using the  
743 enzyme protection assay (EPA) technique described above. In HEK293 cells,  
744 autophagosomes were labelled using the CYTO-ID Autophagy Detection Kit 2.0 (ENZ-  
745 KIT175, Enzo Life Sciences) as recommended by the manufacturer. Briefly, 30 min before  
746 image recording (*i.e.*, 2.5 hpi or 6.5 hpi), the spent media was discarded, and cells were  
747 washed once with the assay buffer. Cells were incubated with the CYTO-ID Green detection  
748 reagent and 5 µg/mL Hoechst 33342 for 30 min at 37 °C and 5% CO<sub>2</sub> protected from light.  
749 Cells were then washed once with the assay buffer and imaged immediately by confocal  
750 microscopy.

751 In organoids, Actin-F was labelled with Sir-Actin dye (1:5000, Cytoskeleton, Denver, CO,  
752 USA) for 4 h prior to infection.

753

#### 754 **Image acquisition and quantification**

755 Images were acquired using a spinning disk confocal microscope (SDCM) (Ti2 CSU-W1,  
756 Nikon, France) with a 60x objective (CFI Plan Apo Lambda NA = 1.40, MRD1605, Nikon) or  
757 using a confocal laser scanning microscope (CLSM) (LSM 800 airyscan, Zeiss, Oberkochen,  
758 Germany) with a 10x objective (Plan-Apochromat 10x/0.45 M27, Zeiss). Image analysis was  
759 performed with the General Analysis 3 module of the NIS software (v5.30, Nikon) or Fiji  
760 software (v1.52p, NIH, USA).

761 In HEK293 cells, YAP immunolabeling was quantified using an automatic macro developed  
762 with the NIS software to measure MFI in the cytoplasmic and nuclear areas and to calculate  
763 the NC ratio by dividing the nuclear MFI by the cytoplasmic MFI. Cytoid quantification was  
764 also performed using the NIS software. Briefly, the images were denoised and binarized in  
765 3D. The Cytoid vesicle count and volume as well as the *S. aureus* volume were measured,  
766 and the colocalization between the *S. aureus* volume and Cytoid vesicle volume was  
767 assessed. The cell area was determined using an extended area of DAPI labeling. For each  
768 cell, the count and mean volume of the Cytoid vesicles were measured. The same method  
769 was used to measure the *S. aureus* volume per cell. Quantifications were performed by  
770 analyzing 2 to 3 fields per well using a 60x objective.

771 For organoid lining layer thickness, quantification was performed with the Fiji software using  
772 cryosections stained with DAPI and dye-labeled phalloidin. Two slices per organoid were  
773 assessed. Quantification was performed on tile images acquired with a 10x objective,  
774 allowing quantification of the entire structure. Images were binarized, and the synovial lining  
775 layer area was automatically selected. The organoid perimeter was then measured. The  
776 lining layer thickness was the result of the synovial lining layer area divided by the perimeter  
777 of the synovial organoid.

778

#### 779 **Luciferase assay**

780 HEK293 cells were transfected in 96-well plates with the 8xGTIIC-luciferase plasmid (firefly  
781 luciferase, # 34615, Addgene, Watertown, MA, US) and the pRL-SV140P plasmid (Renilla  
782 luciferase, # 27163, Addgene), using 0.5 µg of each plasmid and 2 µL of the jetPRIME

783 transfection reagent (Polyplus transfection, New York, NY, USA) in a final volume of 100  $\mu$ L  
784 per well and incubated overnight at 37°C in 5% CO<sub>2</sub>. The next day, the spent medium was  
785 replaced with the fresh complete culture medium, and the cells were incubated for another  
786 24 h at 37°C in 5% CO<sub>2</sub>. The day after, the transfected cells were challenged with *S. aureus*  
787 or supernatant only, as mentioned in the text. After the challenge, the cells were lysed and  
788 luminescence was quantified using the Promega dual glow assay (Promega, Madison, WI,  
789 USA) with a multimodal plate reader (TriStar, Berthold). The blank value was subtracted, and  
790 the firefly luciferase activity was divided by the Renilla luciferase activity to normalize the  
791 results according to the number of cells.

792

### 793 **Protein extraction and western blotting**

794 For HEK293 cells, protein extraction was performed using the Allprep RNA/Protein Kit  
795 (80404 Qiagen Inc., Hilden, Germany). Proteins (10–20  $\mu$ g) were denatured and separated  
796 for 20 min at 200 V before being transferred onto the polyvinylidene difluoride membrane  
797 (IB24002, Thermo Fisher Scientific). The membrane was blocked in TBS Tween 0.1% with  
798 5% skimmed milk and incubated with primary antibody overnight at 4 °C. The membrane was  
799 washed once with washing buffer and incubated with a horseradish peroxidase-conjugated  
800 secondary antibody (31460, Thermo Fisher Scientific; 1:5000) for 1 h at RT. Immunoreactive  
801 protein bands were visualized using the Clarity Western ECL Substrate (Bio-Rad, Hercules,  
802 CA, USA). Western blotting (WB) was performed using the following primary antibodies  
803 purchased from Cell Signaling Technology (Danvers, MA, USA) diluted at 1:1,000: YAP/TAZ  
804 (#8418), LC3A/B (#12741), and 1:5,000: GAPDH (#2118).

805

### 806 **RNA extraction and RT-qPCR**

807 For synovial organoids, lysis was performed using the TRI Reagent (Sigma-Aldrich); three  
808 synovial organoids were pooled together during the lysis step to yield sufficient RNA.

809 For synovial organoids, the aqueous phase was processed following lysis in the TRI Reagent  
810 for RNA extraction and purification. For cell culture, RNA was extracted using the Allprep



811 RNA/Protein Kit (Qiagen). The quality and quantity of RNA were assessed using the  
812 Experion RNA Analysis Kit (BioRad) and QuantIT RiboGreen RNA Assay Kit (Thermo Fisher  
813 Scientific), respectively. Complementary DNA (cDNA) was synthesized using an iscript cDNA  
814 Synthesis Kit (Bio-Rad). Quantitative RT polymerase chain reaction (PCR) was performed  
815 using the CFX96 RealTime System (BioRad) with LightCycler FastStart DNA Master plus  
816 SYBR Green I (Roche Diagnostics, Basel, Switzerland). The results were normalized to the  
817 housekeeping gene expression hypoxanthine-guanine phosphoribosyltransferase (HPRT).  
818 The sequences of the primers used in this study are available upon request.

819

### 820 **Transcriptomic analysis using nCounter Host Response Panel**

821 The nCounter Host Response panel (Nanostring technology), which includes 770 genes  
822 involved in host response processes, was performed with the nCounter Sprint instrument  
823 following the manufacturer's recommendations. Briefly, we used 50 ng of RNA extracted  
824 from WT or YAP<sup>-/-</sup> HEK293 infected (or not) with the HG001 strain at MOI 10 for 7 h (n = 3  
825 per group). All quality controls were performed according to the manufacturer's instructions.  
826 Normalization was performed using the housekeeping genes identified by the geNorm  
827 analysis using the NanoString advance software. The count detection limit was determined  
828 using a threshold based on the negative controls. Data analysis was performed using the  
829 nSolver package (version 3.0) and the Advanced Analysis module (version 1.0.36).  
830 Differential expression and pathway analyses were performed using the nSolver advance  
831 analysis module according to the guidance given by manufacturer's instructions. Genes with  
832 a false discovery rate (FDR)-corrected p-value < 0.05 were considered significantly  
833 differentially expressed.

834

### 835 **Statistical analysis**

836 Data are represented as single values with mean and standard deviation and are expressed,  
837 if indicated in the figure legend, as a percentage of the mean of control values. The results  
838 are representative of at least three independent experiments. Multiple comparisons were

839 performed by analysis of variance (ANOVA) or Kruskal-Wallis test, and post hoc  
840 comparisons were corrected using the FDR method of Benjamini and Hochberg. Results  
841 were considered significantly different when  $p < 0.05$  or  $q < 0.05$ . All statistical analyses were  
842 performed using the GraphPad software (v9.2.0, Prism). The NanoString results were  
843 analyzed using the nSolver software (v4.0, NanoString Technology) and nSolver Advance  
844 Analysis Module (v2.0.134, NanoString Technology).

845 **ACKNOWLEDGMENT**

846 The strain of *Staphylococcus aureus* HG001 was provided by Tarek Msadek (Institut Pasteur,  
847 France). We thank all the members of the GIMAP and LBTO teams for their help and  
848 feedback.

849

850 **AUTHORS CONTRIBUTIONS**

851 RC, EA, and POV designed the experiments. RC performed the experiments, designed and  
852 performed the CRISPR-cas9 based HEK293 mutation and developed the synovial organoid  
853 model. EA contributed to the plasmid design for YAP $\Delta$ TEAD<sup>+/+</sup> cell generation. MT  
854 contributed to the nanostring experiments and CRISPR clone identification. EA, YD, and KR  
855 contributed to protein extraction and WB experiments. AP-transformed *S. aureus* strains for  
856 live-cell microscopy. ED contributed to RNA extraction in the organoid experiments. FV  
857 provided ST80 WT and  $\Delta$ *edinB* strains. RC and EA analyzed the results. RC, EA, and POV  
858 wrote the manuscript. JJ, HM, FV, and FL provided critical corrections to the manuscript.  
859 POV, FL, and JJ obtained funding for this work and supervised the project. All authors have  
860 agreed to the final version of the manuscript.

861

862 **DATA AVAILABILITY**

863 The datasets generated and analyzed during the current study are available from the  
864 corresponding author upon request. Nanostring nCounter data have been deposited on Gene  
865 Expression Omnibus platform under the accession number: GSE197181.

866

867 **FUNDING**

868 This work was supported by a grant from the FINOVI association (#AO13 FINOVI) under the  
869 aegis of the Foundation for the University of Lyon.

870 **FIGURE LEGENDS**

871

872 **Figure 1. *Staphylococcus aureus* toxin EDIN-B prevented YAP activation in HEK293**  
873 **cells**

874 HEK293 cells were cultured at high (A-E) or low density (F). HG001 or ST80 *S. aureus*  
875 infection was at a multiplicity of infection of 10 for 7 h (A-D) or 3 h (E). *S. aureus* were  
876 allowed to contact for 2 h with the cells, and lysostaphin was added at 10 µg/mL for the rest  
877 of the experiments to avoid extracellular *S. aureus* multiplication. A: Confocal representative  
878 z-stack max intensity projection images of YAP (immunolabeling, green), DAPI (nucleus,  
879 blue), *S. aureus* (DsRed, red), and merged. Scale bar: 20 µm. B-D: Quantification of YAP  
880 nuclear mean fluorescence intensity (MFI) (B), YAP cytoplasmic MFI (C), and YAP nuclear  
881 cytoplasmic ratio (D) of HG001-infected cells. E-F: luciferase reporter assay of TEAD  
882 transcription factor activity (8xGTIIC) for ST80 *S. aureus* infection (E) or ST80 strain  
883 supernatant treatment for 24 h (F). Results were expressed as fold change vs. control group  
884 and presented as individual values with mean ± SD, representing three independent  
885 experiments. CTRL: control; WT: wild-type; ST80ΔEB: ST80 EDIN-B-deleted strain; Sp:  
886 supernatant. ANOVA test with false discovery rate (FDR) correction for multiple comparisons  
887 post hoc tests: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

888

889 **Figure 2. YAP transcriptional activity inhibits intracellular *Staphylococcus aureus***  
890 **replication**

891 HEK293 cells were cultured at low (B) or medium density (C-F). HG001 or ST80 *S. aureus*  
892 infection was at a multiplicity of infection of 1 for 3 or 7 h, as indicated. *Staphylococcus*  
893 *aureus* were allowed to contact cells for 2 h, and lysostaphin was added at 10 µg/mL for the  
894 remaining experiments to avoid extracellular *S. aureus* multiplication. A: Electrophorogram of  
895 WT and YAPΔTEAD<sup>+/+</sup> cells showing TTCAAGCCGCCG replacement by AGAAGAAGAAGA.  
896 B: Luciferase reporter assay of TEAD transcription factor activity (8xGTIIC) for WT and  
897 YAPΔTEAD<sup>+/+</sup> cells; C: Representative confocal z-stack max intensity projection images of

898 live cells labeled with DAPI (nucleus, blue) and infected with DsRed *S. aureus* HG001 or  
899 ST80 strains as indicated (red); scale bar 20  $\mu\text{m}$  and 5  $\mu\text{m}$  for zoomed image D: Microscopy  
900 quantification of intracellular HG001 mean volume per cell. E: Quantification of HG001  
901 colony forming unit (CFU) per mL on an agar plate at a ratio of 3 hpi/7 hpi. F: Microscopy  
902 quantification of the intracellular ST80 strain mean volume per cell. For microscopy  
903 quantification (D and F), the total *S. aureus* volume measured in the field was divided by the  
904 number of nuclei in the same field. Results were expressed as fold change vs. control group  
905 and presented as individual values with mean  $\pm$  SD, representing three independent  
906 experiments. WT: wild type; ST80 $\Delta$ EB: ST80 EDIN-B-deleted ST80 strain; CFU: colony-  
907 forming unit. Unpaired t-test (B) or Analysis of variance (ANOVA) test with false discover rate  
908 (FDR) correction for multiple comparison post hoc tests: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

909

910 **Figure 3. YAP promotes host response gene expression important during**  
911 ***Staphylococcus aureus* infection**

912 HEK293 cells were cultured at medium density and infected with HG001 *S. aureus* strain at a  
913 multiplicity of infection of 10 for 7 h. *Staphylococcus aureus* were allowed to contact cells for  
914 2 h with the cells. Subsequently, lysostaphin was added at 10  $\mu\text{g}/\text{mL}$  for the remaining  
915 experiments to avoid extracellular *S. aureus* multiplication. A: Heat map of nCounter  
916 NanoString host response pathways; pathways are listed to the left, the most upregulated  
917 pathways are depicted in orange, and the most downregulated pathways are shown in blue;  
918 each column corresponds to one sample ( $n=3$  / group). C: Volcano plot representation of  
919 differential gene expression in YAP<sup>-/-</sup> infected group versus the baseline of WT infected  
920 group; depicted genes were the most differentially expressed with the combination of a low  
921 p-value and a high fold change; p-value was calculated with the NanoString software based  
922 on t-test corrected with false discovery rate. WT: Wild type; SA: *S. aureus*.

923

924 **Figure 4. YAP/TEAD activity is involved in autophagic flux regulation via lysosomal**  
925 **acidification**

926 HEK293 cells were cultured at medium density and remained uninfected. A: Volcano plot  
927 representation of differential gene expression (nCounter NanoString) in YAP<sup>-/-</sup> control group  
928 versus the baseline of WT control group; depicted genes are autophagic (red) or lysosomal  
929 (green) pathway genes differentially expressed. B-C: Representative western blot results of  
930 LC3A/B -I and -II, and GAPDH (B), with their quantification normalized by GAPDH  
931 expression (C). D: Representative confocal z-stack max intensity projection images of live  
932 cells labeled with DAPI (nucleus, blue) and CytolD (LC3-II vesicles, green). Scale bar: 20  $\mu$ m  
933 (left) and 5  $\mu$ m (right). E: corresponding quantification of the LC3-II positive vesicle count or  
934 mean vesicle volume per cell, as indicated. Each point represents one cell, the number of  
935 analyzed cells per group is indicated; F: Confocal representative z-stack max intensity  
936 projection images of LC3 (immunolabeling, green) and DAPI (nucleus, blue); scale bar: 5  $\mu$ m  
937 G: timeline of LysoSensor experiment; bafilomycin pre-treatment was performed for 2 h, cells  
938 were washed, and the relative 450/550 nm ratio was assessed immediately or 20 min after  
939 LysoSensor addition. H: corresponding results indicating the relative acidity of lysosomes in  
940 control or BafA1-treated cells after 0 or 20 min as indicated. Notably, an increase of 450/550  
941 nm ratio is representative of lysosome alkalinization. Results are expressed as fold change  
942 vs. control group (only in C and H), and presented as individual values with mean  $\pm$  SD (C  
943 and H) or median with interquartile range (E), representing three independent experiments.  
944 WT: wild type; BafA1: Bafilomycin A1. Unpaired t-test (C), Analysis of variance (ANOVA) or  
945 Kruskal-Wallis (KW) test with false discovery rate (FDR) correction for multiple comparisons  
946 post hoc tests: \* p<0.05, \*\* p<0.01, \*\*\* p<0.001.

947

948 **Figure 5. YAP/TEAD transcriptional activity is required to reduce *Staphylococcus***  
949 ***aureus* induced autophagic flux blockage**

950 HEK293 cells were cultured at medium density. HG001 *S. aureus* infection was at a  
951 multiplicity of infection of 1 for 3 or 7 h, as indicated. *Staphylococcus aureus* were allowed to  
952 contact cells for 2 h, and lysostaphin was added at 10  $\mu$ g/mL for the remaining experiments  
953 to avoid extracellular *S. aureus* multiplication. A: Representative confocal (0.5  $\mu$ m thick z-

954 stack) images of live cells labeled with DAPI (nucleus, blue), CytolD (LC3-II vesicles, green),  
955 HG001 (DsRed, red), and merged; white arrowhead: diffused red fluorescence within  
956 autophagic vesicles. White empty arrowhead: disrupted *S. aureus*. scale bar: 5  $\mu$ m. B-C:  
957 corresponding quantification of the LC3-II-positive vesicle count (B) or mean volume (C) per  
958 cell as indicated. Each point represents one cell. The number of analyzed cells per group is  
959 shown. D: Quantification of the relative percentage of colocalization between *S. aureus* and  
960 CytolD labelling (LC3-II vesicles). The results are expressed as fold change vs. the WT 3 hpi  
961 group set at 100%. E-F: Representative western blot results of LC3-I and II, and GAPDH (E),  
962 with their quantification normalized by GAPDH expression (F). Results are expressed as fold  
963 change vs. control group (only in D and F) and presented as individual values with mean  $\pm$   
964 SD (D and F) or median with interquartile range (B and C), representing three independent  
965 experiments. WT: Wild type. Analysis of variance (ANOVA) or Kruskal-Wallis (KW) test with  
966 false discovery rate (FDR) correction for multiple comparisons post hoc tests: \*  $p < 0.05$ , \*\*  
967  $p < 0.01$ , \*\*\*  $p < 0.001$ .

968

969 **Figure 6. YAP promotes inflammatory response during *Staphylococcus aureus***  
970 **infection**

971 HEK293 cells were cultured and infected, as described in Figure 3. A: nCounter NanoString  
972 host response inflammatory gene expression in the four groups; depicted genes were  
973 selected if at least one comparison between two groups gave a corrected  $p$ -value  $< 0.01$ , and  
974 they must be related to chemokine, cytokine, prostaglandin, or inflammasome signaling as  
975 indicated. B: Volcano plot representation of differential gene expression in YAP<sup>-/-</sup> infected  
976 group versus the baseline of WT infected group; depicted genes are chemokine and cytokine  
977 (red circle), leukotriene and prostaglandin (green square), and inflammasome (blue triangle)  
978 pathway genes differentially expressed. C: RT-qPCR quantification of IL6, CXCL8, PTGS2,  
979 and IL1B expression normalized to HPRT expression. Results are expressed as fold change  
980 vs. control group (only in A and C) and presented as histograms (A) or individual values (C)  
981 with mean  $\pm$  SD, representing three independent experiments (C). WT: Wild type; SA: *S.*

982 *aureus*. Analysis of variance (ANOVA) test with false discovery rate (FDR) correction for  
983 multiple comparisons post hoc tests: \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

984

985 **Figure 7. *Staphylococcus aureus* EDIN-B expression decreased YAP activity in a**  
986 **synovial organoid model**

987 Primary fibroblast-like synoviocytes (FLSs) from human osteoarthritic patients (n=3) were  
988 used to form synovial organoids. Organoids were infected with  $1 \times 10^8$  *S. aureus* per mL.  
989 *Staphylococcus aureus* ST80 strains were allowed to contact organoids for 30 min and  
990 imaged immediately (A) or let in contact for 2 h upon agitation, then, lysostaphin was added  
991 at 10  $\mu\text{g/mL}$  for the rest of the experiments to avoid extracellular *S. aureus* multiplication. A:  
992 Representative deconvolved confocal z-stack max intensity projection images of live  
993 organoids labeled with Sir-actin (actin filaments, magenta), ST80 strains (DsRed, red), and  
994 merged images were obtained from the surface of the organoid; scale bar: 25  $\mu\text{m}$ . B-C:  
995 Confocal representative z-stack maximum intensity projection of 30  $\mu\text{m}$  thick cryosections of  
996 the entire organoid (B) or the lining layer (C); #: organoid stromal part, \*: outside of the  
997 organoid, dotted line: limit between lining layer and stromal part, white arrow: local synovial  
998 thickening; Scale bar: 200  $\mu\text{m}$  (B), 25  $\mu\text{m}$  (C). D: Microscopy quantification of synovial lining  
999 layer thickness. n=14 to 15 per group. E: Confocal representative z-stack max intensity  
1000 projection images of 30  $\mu\text{m}$  thick cryosections labeled with YAP (immunolabeling, green),  
1001 DAPI (nucleus, blue), ST80 strains (DsRed, red), phalloidin (actin filaments, magenta), and  
1002 merged; scale bar: 20  $\mu\text{m}$  or 5  $\mu\text{m}$  for zoom. F: RT-qPCR quantification of CTGF, CYR61,  
1003 CXCL8, and PTGS2 expression normalized to HPRT expression, n= 11 to 12 per group.  
1004 Results are expressed as fold change vs. control group and presented as individual values  
1005 with mean  $\pm$  SD, and representative of three independent experiments corresponding to  
1006 three different fibroblast-like synoviocytes (FLS) donors. WT: wild type; ST80 $\Delta$ EB: ST80  
1007 EDIN-B-deleted strain. Analysis of variance (ANOVA) or Kruskal-Wallis (KW) test with false  
1008 discovery rate (FDR) correction for multiple comparisons post hoc tests: \*  $p < 0.05$ , \*\*  $p < 0.01$ ,  
1009 \*\*\*  $p < 0.001$ .











Figure 4.




Figure 5.











Figure 6.

A



B

YAP<sup>-/-</sup> SA vs baseline of WT SA



C

